Efficacy and safety of CGRP monoclonal antibodies for migraine prevention in episodic migraine; a network Meta-analysis

Key Points

• CGRP monoclonal antibodies effectively reduce migraine frequency, improving quality of life.
• The analysis indicates a significant decrease in attack frequency, highlighting their potential benefit in episodic migraine.
• Network meta-analysis compared multiple CGRP treatments against conventional options, ensuring comprehensive results.
• Results suggest CGRP treatments may improve efficacy in migraine management but need further real-world validation.